A method for screening epitope-specific antibodies and the screened antibodies
Through epitope-specific antibody screening methods, antibodies that can efficiently block the binding of PD-1 and PD-L1 were screened, solving the problems of low screening efficiency of antibody library and ineffective antibodies in the prior art, and achieving effective for malignant tumors treat.
Patent Information
- Application Number
- CN201711375292.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2017-12-19
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2037-12-19
AI Technical Summary
The existing antibody library screening technology has low hit rate for functional antibodies specific to epitopes with patent drug potential, resulting in low high-throughput screening efficiency and high cost of later cloning identification, and is unable to effectively block the binding of PD-1 and PD-L1. , resulting in ineffective treatment of PD-1 in some patients.
Using an epitope-specific antibody screening method, the phages specifically bound to the epitope peptide were coupled to the solid phase medium by synthesizing antigen epitope peptides, and phages specifically bound to the epitope peptide were screened from the phage display antibody library, and the phages specifically bound to the epitope peptide were performed on high-expression antigen cells. Further screening was obtained to obtain functional antibodies that specifically bind to human PD-1 molecule. The method includes two rounds of screening steps, the first round of screening antibody libraries, the second round of screening live cells, improve the specificity of screening through circulating screening, obtain variable region sequences of heavy and light chains, and build a full human antibody expression system. Generate IgG4 type antibody.
The epitope-specific functional antibody hit rate is improved. The obtained antibodies can effectively block the binding of PD-1 and PD-L1 at low doses, significantly improving the therapeutic effect on malignant tumors, and reducing the dosage and cost of drugs. .
Smart Images

Figure 171219131049 
Figure 171219131054 
Figure 171219131059
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a method for screening epitope-specific antibodies and the screened antibodies. Background Art
[0002] The "immune escape" of cancer cells is considered to be the main mechanism of tumor occurrence, development and drug resistance. Tumors can protect themselves from the clearance of the immune system by directly or indirectly inhibiting T cell signals. Immune checkpoint therapy for tumors is a type of treatment that regulates T cell activity through a series of pathways such as co-inhibition or co-stimulation signals to enhance anti-tumor immune responses.
[0003] PD-1 (Programmed Cell Death Protein 1, also known as CD279) is a cell surface receptor expressed on activated T cells and pro-B cells. It is an immune checkpoint that has a negative regulatory effect on the immune system and promotes self-tolerance by inhibiting T cell inflammatory activity. More specifically, PD-1 prevents the occurrence of autoimmunity through a dual mechanism of promoting apoptosis of antigen-specific T cells in lymph nodes and reducing apoptosis of regulatory T cells (Treg, also called suppressor T cells).
[0004] PD-1 is encoded by the PDCD1 gene and has a total length of 288 amino acids, of which the first 20 amino acids at the N-terminus are a signal peptide that is removed after maturity, the 21st to 170th amino acids are the extracellular segment, the 171st to 191st amino acids are the transmembrane region, and the 192th to 288th amino acids are the intracellular tail.
[0005] PD-1 can bind to two ligands, PD-L1 and PD-L2, members of the B7 family. In mice, PD-L1 is widely expressed in various organs such as the heart, lungs, thymus, spleen, and kidneys, as well as almost all mouse tumor cell lines, and is highly expressed in a variety of human tumor cells; while the expression of PD-L2 is more limited, mainly in dendritic cells and a few tumor cell lines. Therefore, PD-1 and its ligand PD-L1 have become targets for anti-tumor immunotherapy.
[0006] Currently, two anti-PD-1 targeted therapy drugs have been approved for marketing, namely Opdivo (generic name Nivolumab) and Keytruda (generic name Pembrolizumab). Opdivo's approved indications include unresectable or metastatic melanoma and metastatic squamous non-small cell lung cancer. Keytruda's approved indications include unresectable or metastatic melanoma and non-small cell lung cancer, head and neck squamous cell carcinoma, typical Hodgkin's lymphoma, urothelial carcinoma, microsatellite high instability cancer, etc.
[0007] According to the clinical trial results disclosed in the U.S. FDA drug instructions, Opdivo had an objective response rate (ORR) of 32% (38 / 120) in a clinical trial of 120 patients with unresectable or metastatic melanoma, including 4 patients with complete response (CR) and 34 patients with partial response (PR); in another clinical trial of 117 patients with metastatic squamous non-small cell lung cancer, the objective response rate was 15% (17 / 117). In a randomized, controlled, open, multicenter clinical trial of 834 patients with unresectable or metastatic melanoma, the ORRs of the two trial groups (receiving different doses of Keytruda treatment) were 33% (10 mg / kg every three weeks) and 34% (10 mg / kg every two weeks), with CR rates of 6% and 5%, and PR rates of 27% and 29%, respectively, while the ORR of the control group (anti-CTLA-4 monoclonal antibody Ipilimumab treatment) was 12%; in another randomized, controlled, open, multicenter clinical trial of 305 patients with metastatic non-small cell lung cancer, the ORR of the trial group (Keytruda treatment) was 45% (CR4%, PR41%), while the ORR of the control group (chemotherapy) was 28% (CR1%, PR27%). From the above studies, we can see that although the anti-PD-1 treatments of Opdivo and Keytruda have significantly improved the objective response rate (ORR) compared with chemotherapy and anti-CTLA-4 treatments, only about one-third of patients still benefit, and more than half of the patients cannot achieve disease remission.
[0008] The effectiveness of anti-PD-1 antibodies in treating malignant tumors is mainly related to their blocking effect on PD-1 / PD-L1 binding. The binding epitope and polymorphism of anti-PD-1 antibodies on the PD-1 molecule, as well as the binding affinity (generally expressed by the equilibrium dissociation constant KD value), specificity and other factors will affect the blocking effect of anti-PD-1 antibodies on PD-1 / PD-L1 binding.
[0009] Phage display antibody library is a high-throughput screening technology for antibodies. At present, the industry often uses the extracellular region of the recombinantly expressed target molecule as the target antigen to screen the antibody library. The extracellular region of these target molecules has only one or several functional epitopes, generally composed of 5-15 amino acids, responsible for binding to the ligand. Therefore, only antibodies targeting specific functional epitopes have drug potential. In addition to the functional domains that play a biological function, the recombinantly expressed extracellular region fragments used for antibody library screening also have a large number of dominant antigenic epitopes. Therefore, most of the antibodies screened have only binding activity, but no neutralizing activity that blocks its biological function, and no drug potential. A large number of functional experiments and epitope identification work are required to select functional antibodies with therapeutic effects. There are also cases where synthetic epitope peptides are used to screen antibody libraries. However, since there may be differences between synthetic epitope peptides and antigenic epitopes in natural conformation, antibodies that can bind to epitope peptides may not be able to bind to antigenic epitopes on the surface of living cells. In summary, the existing antibody library screening technology has a low hit rate for epitope-specific functional antibodies with druggable potential, which seriously affects the efficiency of high-throughput screening and increases the cost of subsequent cloning identification. Summary of the invention
[0010] The present invention provides a method for efficiently screening an antibody library, which can solve the problem that the existing antibody library screening technology has a low hit rate for epitope-specific functional antibodies with druggable potential. The present invention also provides an anti-PD-1 monoclonal antibody obtained by this screening method, which has a different binding epitope from Nivolumab and Pembrolizumab, and has high affinity and good specificity, and can solve the problem that some patients are ineffective for existing anti-PD-1 treatment.
[0011] The technical solution of the present invention is as follows:
[0012] A method for screening epitope-specific functional antibodies comprises the following two screening steps:
[0013] Step 1: For antigen epitopes with biological functions, synthesize antigen epitope peptides and couple them to solid phase media, perform the first round of screening from the phage display antibody library, obtain phages that specifically bind to the epitope peptides and amplify them;
[0014] Step 2: Obtain or construct a cell line that highly expresses the target antigen on the cell surface, and use living cells to further screen the phages obtained from the first round of screening for phages that bind to the cell surface antigen to prepare functional antibodies.
[0015] To enhance the specificity of screening, step 1 and step 2 can be sequentially cycled for 2-5 rounds. The technical flow chart for antibody screening according to this technical scheme can be found in the attached Figure 1 .
[0016] In step 1, the amino acid sequence of the antigenic epitope with biological function can be obtained by protein crystallization, affinity analysis of fragment deletion / point mutation to ligand / receptor, software prediction and the like. The antigenic epitope peptide is a cyclic peptide composed of 10 to 15 amino acids, and the amino acid composition of the cyclic peptide meets the following conditions:
[0017] (1) There is only one cysteine in the cyclic peptide, and the cyclic peptide is covalently coupled to the solid phase medium through the thiol group of the cysteine;
[0018] (2) There is a connecting peptide consisting of 2 or 3 amino acids on each side of the cysteine in the cyclic peptide, and the amino acids that constitute the connecting peptide can only be glycine or proline;
[0019] (3) The cyclic peptide contains an antigenic epitope consisting of 5-8 amino acids.
[0020] Preferably, the connecting peptide segment connected to the amino terminal of cysteine in the cyclic peptide is completely composed of glycine, and the connecting peptide segment connected to the carboxyl terminal of cysteine contains 1 to 2 prolines.
[0021] Specifically, when used to screen monoclonal antibodies against the functional epitope composed of amino acids 75-82 of human PD-1 (amino acid sequence is QTDKLAAF), the antigen epitope peptide used in step one is cyclic and conforms to the sequence recorded in SEQ ID NO: 13; the cell line used in step two is a cell line that highly expresses human PD-1 on the cell surface. Preferably, the cell line is a cell line that expresses an exogenous human PD-1 gene transformed by genetic recombination technology, and the cell line does not express PD-1 in its natural state (i.e., before genetic modification). Preferably, the expression density of human PD-1 on the cell surface is 10,000 / cell to 500,000 / cell.
[0022] An antibody screened by the above method can specifically bind to the 75th to 82nd amino acids of the human PD-1 molecule starting from the N-terminus (amino acid sequence is QTDKLAAF), and the complementary determining regions CDR1, CDR2, and CDR3 of the heavy chain of the antibody have the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and the complementary determining regions CDR1, CDR2, and CDR3 of the light chain have the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively.
[0023] Preferably, the heavy chain variable region has the amino acid sequence of SEQ ID NO: 7, and the light chain variable region has the amino acid sequence of SEQ ID NO: 8.
[0024] Preferably, the heavy chain is of IgG4 subtype and has the amino acid sequence of SEQ ID NO: 9, and the light chain has the amino acid sequence of SEQ ID NO: 10.
[0025] Preferably, the heavy chain is encoded by the nucleotide sequence of SEQ ID NO: 11 and the light chain is encoded by the nucleotide sequence of SEQ ID NO: 12.
[0026] The antibody is secreted and expressed by Chinese hamster ovary cells (CHO cells).
[0027] Competitive inhibition assay (Example 6) and point mutation assay (Example 7) showed that the antibody has different binding epitopes with Nivolumab and Pembrolizumab, and can also bind to the D85G point mutation PD-1 that cannot bind to Pembrolizumab.
[0028] The antibody has a lower IC50 value than Nivolumab and Pembrolizumab (Example 5), can enhance the ability of human T lymphocytes to respond to SEB stimulation (Example 8), can more effectively block the binding of PD-1 and PD-L1 at low doses, and has a therapeutic effect on malignant tumors at lower doses (Example 9).
[0029] The antibody can be used alone or in combination with other drugs and excipients to prepare drugs for treating malignant tumors and immune system diseases.
[0030] The beneficial effects of the present invention include that the antibody library screening method of the present invention can increase the hit rate of epitope-specific functional antibodies to more than 30%, greatly reducing the number and cost of clone identification. The anti-PD-1 monoclonal antibody of the present invention has different human PD-1 binding epitopes from Nivolumab and Pembrolizumab, can also bind to point mutation PD-1 that cannot bind to Pembrolizumab, and has high affinity with PD-1, has a lower IC50 value, and more effectively blocks the binding of PD-1 to PD-L1 at low doses, and has a therapeutic effect on malignant tumors at low doses, and the application of low-dose antibodies has positive significance for reducing drug stimulation to the body, reducing drug costs and prices. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 Epitope-specific functional antibody screening technology roadmap
[0032] Figure 2 Example 5 Competitive inhibition experiment results of fully human anti-PD-1 monoclonal antibody 5L12 on PD-1 / PD-L1 binding
[0033] Figure 3 Example 6 Competitive inhibition experiment results of other anti-PD-1 antibodies on the binding of fully human anti-PD-1 monoclonal antibody 5L12 to PD-1
[0034] Figure 4 Example 7 ELISA test of the binding ability of the fully human anti-PD-1 monoclonal antibody 5L12 to the D85G mutant PD-1
[0035] Figure 5 Example 8: Test results of the fully human anti-PD-1 monoclonal antibody 5L12 for enhancing the ability of human T lymphocytes to respond to SEB stimulation
[0036] Figure 6 Example 9 Results of high-dose group of tumor inhibition experiment of fully human anti-PD-1 monoclonal antibody 5L12 in animal model
[0037] Figure 7 Example 9 Result graph of low-dose group of tumor inhibition experiment of fully human anti-PD-1 monoclonal antibody 5L12 in animal model. DETAILED DESCRIPTION
[0038] Example 1: Screening of phage display antibody library using synthetic PD-1 epitope peptides
[0039] (1) Epitope peptide synthesis and magnetic bead coupling
[0040] According to the sequence of SEQ ID NO: 13, a human PD-1 cyclic epitope peptide was chemically synthesized (commissioned to be synthesized by Sangon Biotech (Shanghai) Co., Ltd.), which includes the 75th to 82nd amino acids of human PD-1 QTDKLAAF, as well as cysteine M for magnetic bead coupling and connecting peptides consisting of 3 amino acids on both sides, with a molecular weight of 1475 Da. The synthesized epitope peptide was dissolved in PBS (phosphate buffer, pH 7.2, containing 20mM sodium phosphate, 150mM sodium chloride) at 10mg / mL for later use;
[0041] 2 mL of amino-derivatized magnetic beads (Thermofisher Scientific, catalog number 21352, 2.5 g per mL of beads, containing approximately 12 µmol of amino groups) were washed three times with 2 mL of PBS, and the beads were separated magnetically;
[0042] Dissolve Sulfo-SMCC (Thermofisher Scientific, Cat. No. 22122) in PBS at a concentration of 4.8 mg / mL, take 200 μL and mix with the above magnetic beads, react at 4°C for 2 hours;
[0043] The magnetic beads were separated and washed with PBS, and the magnetic beads were divided into two parts. One part was resuspended in 1 mL of PBST containing 1% BSA (PBS containing 0.1% Tween 20), which was recorded as magnetic beads A; 5 mL of cyclic epitope peptide was added to the other part, and the reaction was carried out at 4°C for 2 hours. The magnetic beads were separated and washed with PBST, and resuspended in 1 mL of PBST containing 1% BSA, which was recorded as magnetic beads B.
[0044] (2) Screening of phage display antibody library
[0045] 20 mL of blood was collected from 50 healthy volunteers, mixed, and a phage display antibody library was constructed according to the method in the literature "Construction and diversity analysis of natural human IgG Fab phage antibody library" (Chinese Journal of Immunology, 2010, 26 (11): 1007-1010).
[0046] The magnetic beads A prepared in step (1) were mixed with 1 mL of phage display antibody library (5×10^12 PFU) diluted with PBST containing 1% BSA, and the mixture was rotated at room temperature for 1 hour. The magnetic beads A were removed by magnetic force, and the magnetic beads B prepared in step (1) were added. The mixture was rotated at room temperature for 1 hour, and the magnetic beads B were separated by magnetic force. The magnetic beads B were washed three times with PBST, and 0.2 mol / L Lycine-HCl (pH 2.2) solution was added and gently shaken for 20 min to wash off the phages on the magnetic beads B, and then neutralized with 1 mol / L Tris-HCl (pH 9.1). The obtained phages were infected with Escherichia coli (E. coli) for amplification to form a secondary library, which was stored for later use.
[0047] Example 2: Secondary screening of functional antibodies in living cells with high PD-1 expression
[0048] (1) Construction of cell lines that highly express PD-1 on the cell surface
[0049] The full-length PD-1 coding gene (PDCD1 gene, containing the N-terminal signal peptide coding sequence, for the specific sequence, see NCBI Reference Sequence: NM_005018.2) was cloned and inserted into the pcDNA3.1 expression vector. After amplification in Escherichia coli (E. coli), the 293T cells (ATCC No. CRL-3216) were transfected and high-expressing cell lines were screened. The expression of PD-1 was detected by flow cytometric detection and quantitation of the epidermal growth factor receptor in comparison to Scatchard analysis in human bladder carcinoma cell lines. Cytometry. 1994 Sep 1;17(1):75-83 and Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007 Mar 1;13(5):1552-61” was used to determine the PD-1 expression density on the surface of each cell line. The cell line with the highest expression density, numbered 2H-3, was selected. The average PD-1 expression density on the surface of cell line 2H-3 was 12,000 per cell. The cells were suspended and cultured in 293 SFM II serum-free medium (ThermofisherScientific, catalog number 11686029) to expand the cell number to more than 5×10^6.
[0050] (2) Screening of anti-PD-1 antibodies in living cells
[0051] The blank 293T cells growing in the logarithmic phase were resuspended in 1 mL of DMEM culture medium at a density of 1×10^6 cells / mL, and the phage obtained by screening in Example 1 (2) (resuspended in 1 mL of DMEM culture medium after centrifugation) was added, mixed and incubated at 37°C for 1 hour, centrifuged at low speed to remove the cells, and the process was repeated once to remove the ineffective antibodies bound to the 293T cells and reduce the background value of the screening; then 5×10^5 2H-3 cells with high expression of PD-1 prepared in Example 2 (1) were added to the supernatant of the centrifugation, mixed and incubated at 37°C for 1 hour, centrifuged at low speed to harvest the cells, and the phage was washed from the cells with 1.5 volumes of 76 mM citric acid solution (pH 2.5), and then neutralized with 0.5 volumes of Tris-HCl (pH 7.4), and the obtained phage was infected with Escherichia coli (E. coli) for amplification.
[0052] The phages obtained above were screened for two rounds according to the screening methods of Example 1 (2) and Example 2 (2). The phages finally obtained were monocloned and amplified. 60 clones were selected and the affinity and binding epitope of phage to PD-1 were identified by ELISA (refer to the Phage-ELISA identification method of "Journal of Immunology, Vol. 28, No. 6, June 2012: 489-496"). The recombinantly expressed full-length protein of the extracellular segment of human PD-1 (amino acids 20-170) and the chemically synthesized amino acids 75-82 of human PD-1 (sequence Q TDKLAAF) were coated on a 96-well plate, and chemically synthesized short peptides with sequences such as LDSPDR, LAPKAQ, RSQPGQ were used as negative controls to coat the 96-well plate. Then, phages and HRP-labeled anti-phage antibodies were added, and the binding was detected by adding HRP substrate for color development reaction. Flow cytometry was used to identify the affinity of phages for PD-1 on the surface of living 2H-3 cells. 22 clones that were positive for PD-1 binding by both ELISA and flow cytometry and bound to the specific epitope of PD-1 (amino acids 75-82 QTDKLAAF) were obtained, with a positive rate of 36.67%.
[0053] Example 3: Construction of a fully human anti-PD-1 monoclonal antibody expression system
[0054] (1) Identification of heavy and light chain variable regions
[0055] From the 22 phage positive clones finally obtained in Example 2, 5 clones with higher affinity identified by ELISA were selected for sequencing, and a clone numbered 5L12 was selected for further development. The sequencing results showed that the heavy chain variable region of 5L12 had an amino acid sequence of SEQ ID NO: 7, and the light chain variable region had an amino acid sequence of SEQ ID NO: 8. Further antibody sequence analysis showed that the complementary determining regions CDR1, CDR2, and CDR3 of the heavy chain had amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and the complementary determining regions CDR1, CDR2, and CDR3 of the light chain had amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively.
[0056] (2) Construction and transfection of expression vector
[0057] Using the light and heavy chain variable region gene sequences of 5L12 as templates, the heavy chain gene (IgG4 type) and light chain gene of the fully human antibody were synthesized by overlapping PCR, wherein the coding sequence of the heavy chain was the nucleotide sequence of SEQ ID NO: 11, the coding sequence of the 5'-end signal peptide of the heavy chain was the nucleotide sequence of SEQ ID NO: 14, and the coding sequence of the light chain was the nucleotide sequence of SEQ ID NO: 12. The coding sequences of the heavy chain and light chain were inserted into the pcDNA3.1(+) vector (Invitrogen) to construct the expression vector pcDNA3.1-anti-PD-1 of the fully human anti-PD-1 monoclonal antibody. The CHO-K1 cells (ATCC No. CRL-9618) were transfected using the Lipofectamine2000Reagent kit. Positive clones were screened using G418 and Zeocin. Then, the cell culture supernatant was taken and the high-expressing cell lines were screened using the ELISA method. The specific experimental process of transfection and screening was carried out according to the embodiment of patent CN201010125241 (authorization announcement No. CN102167742B).
[0058] (3) Small-scale expression and purification
[0059] The screened high-expressing cell lines were expanded and cultured in CHO cell serum-free medium, and the fully human antibody 5L12 was separated and purified using a Protein A affinity column (GE product). The purified antibody was dialyzed with PBS and finally quantified by ultraviolet absorption method.
[0060] Example 4. Determination of affinity of fully human anti-PD-1 monoclonal antibody 5L12
[0061] The affinity of the fully human anti-PD-1 monoclonal antibody 5L12 prepared in Example 3 to human PD-1 was determined by surface plasmon resonance (SPR). The BIACORE3000 system was used to couple the sensor chip with the purified 5L12 antibody and operate according to the operating instructions of the system to detect the affinity of 5L12 to the full-length protein of the extracellular segment of PD-1 recombinantly expressed by CHO cells (NCBI reference sequence NM_005018.2 amino acids 20-170) and the chemically synthesized PD-1 amino acids 75-82 (sequence QTDKLAAF) and short peptides with sequences LDSPDR, LAPKAQ, and RSQPGQ. The test results are shown in Table 1. The affinity of 5L12 to the full-length extracellular segment of PD-1 and the epitope peptide QTDKLAAF is 10 -11 M-level.
[0062] Table 1 Results of SPR determination of affinity between fully human anti-PD-1 monoclonal antibody 5L12 and different peptides
[0063]
[0064] Example 5: Competitive inhibition experiment of PD-1 / PD-L1 binding by fully human anti-PD-1 monoclonal antibody 5L12
[0065] The protein to be labeled, PD-L1 (extracellular segment of human PD-L1 recombinantly expressed by CHO cells), was diluted to a concentration of 1% (mass-volume ratio) with 0.025M carbonate buffer at pH 9.5 and placed in a dialysis bag. FITC was prepared into a 0.1 mg / ml solution in the same buffer and placed in a small beaker. The dialysis bag was immersed in the FITC solution and stirred at 4°C in the dark for 24 hours. The labeled solution in the dialysis bag was removed and passed through a Sephadex G-50 column to remove free fluorescein, and the fluorescent antibody FITC-PD-L1 was collected for later use.
[0066] Genetically recombinant 293T cells expressing human PD-1 were cultured at 1×10 6 The cells were resuspended at a density of 1.5 cells / ml in a PBS solution at pH 7.2; a fixed subsaturation concentration of fluorescently labeled protein FITC-PD-L1 was mixed with 4× serial dilutions of unlabeled purified antibody 5L12, Nivolumab (Opdivo), Pembrolizumab (Keytruda), and human IgG (control), respectively, and added to the cell suspension. The cells were incubated at 4°C for 60 min, harvested by centrifugation, washed twice with 1% FCS-PBS buffer, and the cell fluorescence intensity was detected by flow cytometry and analyzed with Cellquest software. Three replicate tubes were set for each concentration of the competing antibody, and the half-maximal inhibitory concentration IC50 value was calculated. The maximum fluorescence intensity represents the average fluorescence intensity obtained in the absence of the competing antibody.
[0067] The experimental results are shown in Figure 2 , indicating that the antibody 5L12 can completely block the binding of the fluorescently labeled antibody FITC-PD-L1 to 293T cells expressing PD-1 on the surface, and its IC50 value is about 30 ng / mL, which is 1 / 20 and 1 / 2 of Nivolumab and Pembrolizumab respectively, indicating that 5L12 can more effectively block the binding of PD-1 and its ligand, and the minimum dose that can exert the effect is lower.
[0068] Example 6: Competitive inhibition experiment of other anti-PD-1 antibodies on the binding of fully human anti-PD-1 monoclonal antibody 5L12 to PD-1
[0069] 5L12 was labeled with FITC using the method of Example 5 to prepare FITC-5L12 fluorescent antibody for later use.
[0070] Genetically recombinant 293T cells expressing human PD-1 were cultured at 1×10 6Cells were resuspended at a density of 1.54 cells / ml in a PBS solution at pH 7.2; a fixed subsaturation concentration of fluorescently labeled protein FITC-5L12 was mixed with 10× serial dilutions of unlabeled antibodies Nivolumab (Opdivo), Pembrolizumab (Keytruda), and human IgG (control), respectively, and added to the cell suspension, incubated at 4°C for 60 min, harvested by centrifugation, washed twice with 1% FCS-PBS buffer, and the cell fluorescence intensity was detected by flow cytometry and analyzed with Cellquest software. Three replicate tubes were set for each concentration of the competing antibody, and the maximum fluorescence intensity represented the average fluorescence intensity obtained in the absence of the competing antibody.
[0071] The experimental results are shown in Figure 3 The results showed that Pembrolizumab had a competitive inhibitory effect on the binding of 5L12 to human PD-1, while Nivolumab had no obvious competitive inhibitory effect on 5L12, which indicates that the binding epitope of 5L12 on human PD-1 is different from that of Nivolumab (the main binding epitope is 25LDSPDR30, reference: An unexpected N-terminal loop inPD-1 dominates binding by nivolumab. Nature Communications, 2017, 8: 14369), but is close to that of Pembrolizumab (the main binding epitope is Pro83~Gly90, reference: High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to thehuman PD-1. Scientific Reports. 2016, 6, Article number: 35297), or the binding of Pembrolizumab to PD-1 spatially hinders the binding of 5L12 to PD-1.
[0072] Example 7: Ability of fully human anti-PD-1 monoclonal antibody 5L12 to bind to D85G mutated PD-1
[0073] Through gene recombination, the aspartic acid at position 85 of human PD-1 was mutated to glycine (D85G mutation), and the genes encoding the human PD-1 extracellular segment and the human PD-1 extracellular segment (D85G) were inserted into the pcDNA3.1 vector and transfected into CHO cells for transient expression and purification.
[0074] The purified human PD-1 extracellular segment and human PD-1 extracellular segment (D85G) protein at a concentration of 1 mg / mL were coated on a 96-well plate at 100 μL / well, 5L12 was diluted 10× from 1 mg / mL and added to the 96-well plate at 100 μL / well, and then HRP-labeled rabbit anti-human IgG was added for color development and the data was read using an enzyme reader. ELISA results are shown in Figure 4 The results showed that 5L12 could bind to both the extracellular segment of human PD-1 and the extracellular segment of human PD-1 (D85G), while Pembrolizumab was reported to be unable to bind to the D85G mutated PD-1 (reference: Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Research 2017.27:147-150.), indicating that 5L12 and Pembrolizumab have different binding sites.
[0075] Example 8: Testing of the ability of fully human anti-PD-1 monoclonal antibody 5L12 to enhance the response of human T lymphocytes to SEB stimulation
[0076] Peripheral blood from healthy volunteers was diluted 1:10 into cell culture medium, and whole blood was plated (150 μL per well) into 96-well plates. The plates were pre-incubated with 10× serial dilutions of fully human anti-PD-1 monoclonal antibody 5L12 for 30-60 minutes, and then 1 μg / mL of Staphylococcal enterotoxin B (SEB) was added. The plates were cultured for 2-4 days, and the supernatants were collected. The IL-2 content was measured by ELISA. The results are shown in Table 1. Figure 5 , indicating that 5L12 can increase the IL-2 production of whole blood cells under SEB stimulation, and the IL-2 level is correlated with the added dose of 5L12.
[0077] Example 9: Tumor inhibition experiment of fully human anti-PD-1 monoclonal antibody 5L12 in animal models
[0078] 1. Construction of human PBMC immune reconstitution mice
[0079] Human PBMC (peripheral blood mononuclear cells) from healthy donors were isolated using human lymphocyte separation medium and 8 × 10 7 / mL resuspended in RPMI-1640 medium for later use; NOD / SCID adult mice with serum mouse IgG <5μg / mL were selected and injected with 2×10 7PBMC cells were collected from the retro-orbital venous plexus of mice on days 0, 14, 28, 42, and 56, and the contents of CD3+T cells and CD19+B cells were detected by flow cytometry using PE-labeled mouse anti-human CD3 monoclonal antibody and FITC-labeled mouse anti-human CD19 monoclonal antibody. The content of human IgG in mouse serum was determined by ELISA to determine the effect of immune reconstitution.
[0080] 2. Construction of mouse tumor model and treatment with anti-human PD-1 antibody 5L12
[0081] Human non-small cell lung cancer cell line HCC827 (highly expressing PD-L1) was cultured at 1×10 6 The cells / mouse were subcutaneously implanted into human PBMC immune reconstituted mice. After implantation, the tumors grew to 250 mm. 2 Anti-PD-1 treatment was then started. The mice were divided into a high-dose group and a low-dose group. The high-dose group was given 3 mg / kg of 5L12 (dissolved in PBS at a concentration of 1 mg / mL), Nivolumab, and Pembrolizumab, once every 10 days for 4 times, and the tumor size was measured with a caliper every week; the low-dose group was adjusted to 0.5 mg / kg, and other experimental methods remained unchanged; and PBS was used as a control.
[0082] The experimental results are shown in Figure 6 and Figure 7 , indicating that 5L12 can significantly inhibit tumor growth at low doses, and the effective dose is significantly lower than that of Nivolumab and Pembrolizumab. Sequence Listing <110> Taizhou Mybiotech Pharmaceutical Co., Ltd. <120> A method for screening epitope-specific antibodies and the screened antibodies <130> 2017 <160> 14 <170> SIPOSequenceListing 1.0 <210> 1 <211> 7 <212> PRT <213> Artificial Sequence() <400> 1 Gly Tyr Thr Phe Thr Ser Tyr 1 5 <210> 2 <211> 6 <212> PRT <213> Artificial Sequence() <400> 2 Tyr Pro Ser Thr Gly Tyr 1 5 <210> 3 <211> 8 <212> PRT <213> Artificial Sequence() <400> 3 Gly Val Arg Tyr Tyr Phe Asp Tyr 1 5 <210> 4 <211> 17 <212> PRT <213> Artificial Sequence() <400> 4 Lys Ser Ser Gln Ser Leu Leu Asp Ser Ser Thr Arg Lys Asn Tyr Leu 1 5 10 15 Ala <210> 5 <211> 7 <212> PRT <213> Artificial Sequence() <400> 5 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 6 <211> 7 <212> PRT <213> Artificial Sequence() <400> 6 Lys Gln Ser Tyr Asn Leu Trp 1 5 <210> 7 <211> 117 <212> PRT <213> Artificial Sequence() <400> 7 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met Leu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Tyr Pro Ser Thr Gly Tyr Thr Glu Tyr Ser Glu Asn Phe 50 55 60 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Val Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 8 <211> 113 <212> PRT <213> artificial sequence() <400> 8 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Ser Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys 35 40 45 Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Lys Gln 85 90 95 Ser Tyr Asn Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Angry <210> 9 <211> 444 <212> PRT <213> artificial sequence() <400> 9 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met Leu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Tyr Pro Ser Thr Gly Tyr Thr Glu Tyr Ser Glu Asn Phe 50 55 60 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Val Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 10 <211> 219 <212> PRT <213> artificial sequence() <400> 10 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Ser Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys 35 40 45 Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Lys Gln 85 90 95 Ser Tyr Asn Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 11 <211> 1332 <212> DNA <213> Artificial Sequence () <400> 11 gaggtgcagc tggtggagtc cggcggcggc ctggtgcagc ccggcggctc cctgcggctg 60 tcctgcgccg cctccggcta caccttcacc tcctactgga tgctgtgggt gcggcaggcc 120 cccggcaagg gcctggagtg ggtgtcctac atctacccct ccaccggcta caccgagtac 180 tccgagaact tcaaggaccg gttcaccatc tcccgggaca actccaagaa caccctgtac 240 ctgcagatga actccctgcg ggccgaggac accgccgtgt actactgcgc ccggggcgtg 300 cggtactact tcgactactg gggccagggc accctggtga ccgtgtcctc cgcctccacc 360 aagggcccct ccgtgttccc cctggccccc tgctcccggt ccacctccga gtccaccgcc 420 gccctgggct gcctggtgaa ggactacttc cccgagcccg tgaccgtgtc ctggaactcc 480 ggcgccctga cctccggcgt gcacaccttc cccgccgtgc tgcagtcctc cggcctgtac 540 tccctgtcct ccgtggtgac cgtgccctcc tcctccctgg gcaccaagac ctacacctgc 600 aacgtggacc acaagccctc caacaccaag gtggacaagc gggtggagtc caagtacggc 660 cccccctgcc ccccctgccc cgcccccgag ttcctgggcg gcccctccgt gttcctgttc 720 ccccccaagc ccaaggacac cctgatgatc tcccggaccc ccgaggtgac ctgcgtggtg 780 gtggacgtgt cccaggagga ccccgaggtg cagttcaact ggtacgtgga cggcgtggag 840 gtgcacaacg ccaagaccaa gccccgggag gagcagttca actccaccta ccgggtggtg 900 tccgtgctga ccgtgctgca ccaggactgg ctgaacggca aggagtacaa gtgcaaggtg 960 tccaacaagg gcctgccctc ctccatcgag aagaccatct ccaaggccaa gggccagccc 1020 cgggagcccc aggtgtacac cctgcccccc tcccaggagg agatgaccaa gaaccaggtg 1080 tccctgacct gcctggtgaa gggcttctac ccctccgaca tcgccgtgga gtgggagtcc 1140 aacggccagc ccgagaacaa ctacaagacc accccccccg tgctggactc cgacggctcc 1200 ttcttcctgt actcccggct gaccgtggac aagtcccggt ggcaggaggg caacgtgttc 1260 tcctgctccg tgatgcacga ggccctgcac aaccactaca cccagaagtc cctgtccctg 1320 tccctgggca ag 1332 <210> 12 <211> 657 <212> DNA <213> Artificial Sequence () <400> 12 gacatccaga tgacccagtc cccctcctcc ctgtccgcct ccgtgggcga ccgggtgacc 60 atcacctgca agtcctccca gtccctgctg gactcctcca cccggaagaa ctacctggcc 120 tggtaccagc agaagcccgg caaggccccc aagctgctga tctactgggc ctccacccgg 180 gagtccggcg tgccctcccg gttctccggc tccggctccg gcaccgactt caccctgacc 240 atctcctccc tgcagcccga ggacttcgcc acctactact gcaagcagtc ctacaacctg 300 tggaccttcg gccagggcac caaggtggag atcaagcgga ccgtggccgc cccctccgtg 360 ttcatcttcc ccccctccga cgagcagctg aagtccggca ccgcctccgt ggtgtgcctg 420 ctgaacaact tctacccccg ggaggccaag gtgcagtgga aggtggacaa cgccctgcag 480 tccggcaact cccaggagtc cgtgaccgag caggactcca aggactccac ctactccctg 540 tcctccaccc tgaccctgtc caaggccgac tacgagaagc acaaggtgta cgcctgcgag 600 gtgacccacc agggcctgtc ctcccccgtg accaagtcct tcaaccgggg cgagtgc 657 <210> 13 <211> 15 <212> PRT <213> Artificial Sequence () <400> 13 Cys Pro Pro Ala Gln Thr Asp Lys Leu Ala Ala Phe Ala Ala Ala 1 5 10 15 <210> 14 <211> 66 <212> DNA <213> Artificial Sequence () <400> 14 atggattttc aggtgcagat tttcagcttc ctgctaatca gtgcctcagt cataatatcc 60 agagga 66
Claims
1. An anti-human PD-1 antibody that can specifically bind to the extracellular segment of the human PD-1 molecule, characterized in that: The amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 of the heavy chain are SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and the amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 of the light chain are SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively.
2. The antibody according to claim 1, characterized in that The heavy chain variable region has the amino acid sequence of SEQ ID NO: 7, and the light chain variable region has the amino acid sequence of SEQ ID NO:
8.
3. The antibody according to claim 1, characterized in that The heavy chain has the amino acid sequence of SEQ ID NO: 9, and the light chain has the amino acid sequence of SEQ ID NO:
10.
4. The antibody according to claim 1, characterized in that The heavy chain is encoded by the nucleotide sequence of SEQ ID NO: 11, and the light chain is encoded by the nucleotide sequence of SEQ ID NO:
12.
5. A composition comprising the antibody according to claim 1 and a pharmaceutically acceptable carrier.
6. Use of the antibody of claim 1, 2, 3 or 4 or the composition of claim 5 in the preparation of a drug for treating, preventing or diagnosing cancer, wherein the cancer is unresectable or metastatic melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin's lymphoma, or urothelial carcinoma.
Citation Information
Patent Citations
Human monoclonal antibody against HER2, preparation method and purpose thereof
CN102167742B
Novel tumor antigen cyclopeptide
CN104292308A
Human anti-HER2 monoclonal antibody with high activity, and preparation method and application thereof
CN104447993A
Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CN1649900A
GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US20060275288A1
